Where does Golden Biotechnology Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Golden Biotechnology Corporation ranks #26,393 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Golden Biotechnology Corporation hold?

Golden Biotechnology Corporation holds 10 US utility patents granted between 2016 and 2023, spanning 5 technology areas.

What is Golden Biotechnology Corporation's Innovation Score?

Golden Biotechnology Corporation has an Innovation Score of 28.7 out of 100 (28th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Golden Biotechnology Corporation focus on?

Golden Biotechnology Corporation's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 9 patents, ranking #2,057 of 6,058 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Golden Biotechnology Corporation's patent grant rate increasing or decreasing?

Golden Biotechnology Corporation's recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Golden Biotechnology Corporation's patents?

Golden Biotechnology Corporation's patents average 12.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Golden Biotechnology Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Golden Biotechnology Corporation

USPTO PatentsView assignee record - 10 granted patents across 5 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Golden ranks #26,393 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 5 technology areas.

#26,393
of 49,997 US assignees by volume: 28th percentile
by Innovation Score (28.7/100): 12.5
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R26393 · US Corporation #26,393 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #26,393/49,997
PHOTO-FINISH Glaston Finland Oy
CPC-NARROW A61P · 5 areas
INNOV-THIN 28.7/100
CLAIMS-RICH 12.5 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Glaston Finland Oy (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Golden’s 28.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (29%) Velocity 5.0 pts (17%) Breadth 7.9 pts (28%) Claim depth 7.5 pts (26%)

Qualcomm Incorporated · highest

85
Golden Biotechnology · this assignee

29
3D Lighting… · lowest

7

What this shows Golden's Innovation Score is 28.7/100 (28th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Golden?

Each dot is one of Golden’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Golden’s own 12.5 claims/patent is ABOVE the 11.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Golden vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Golden's grants concentrate

Golden Biotechnology Corporation is a focused PatentsView assignee: 5 CPC subclasses with 90% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2018. By volume, Golden sits between Glaston Finland Oy and Grand Valley State University.

Golden's three-year grant acceleration

Golden Biotechnology Corporation shows 3 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Glaston Finland Oy

10
Gleim Conferencing

10
Globe Composite S…

10
Go-tech Energy

10
Goodman Global Gr…

10
Gouda-torgerson B…

10
Grand General Acc…

10
Grand Valley Stat…

10
Golden Biotechnol… ◀

10

What this shows Golden holds 10 patents at rank #26,408, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Golden

By rank, the assignees closest to #26,408 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Golden's primary technology class.

Golden's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 28th percentile higher than 28% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Golden Biotechnology Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	20.0%
2018	1	10.0%
2019	1	10.0%
2020	1	10.0%
2021	2	20.0%
2022	2	20.0%
2023	1	10.0%

Which technologies does Golden Biotechnology Corporation patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07C - Acyclic OR Carbocyclic Compounds 5

C07D - Heterocyclic Compounds 3

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Golden Biotechnology Corporation's patent record in context - here's where to go next.

Golden Biotechnology Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 90% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #26,393 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Golden Biotechnology Corporation against Glaston Finland Oy, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.